Published by Josh White on 27th October 2025
(Sharecast News) - 4basebio said on Monday that a global tier-one pharmaceutical partner had started dosing patients in a phase one and two US clinical trial using an mRNA therapy developed with the company's proprietary 'opDNA' synthetic DNA template, marking what it called a major milestone for the technology's adoption in advanced genetic medicines.